Skip to main content
Erschienen in: Drugs & Aging 10/2010

01.10.2010 | Original Research Article

Could Geriatric Characteristics Explain the Under-Prescription of Anticoagulation Therapy for Older Patients Admitted with Atrial Fibrillation?

A Retrospective Observational Study

verfasst von: Sandra De Breucker, Gertraud Herzog, Dr Thierry Pepersack

Erschienen in: Drugs & Aging | Ausgabe 10/2010

Einloggen, um Zugang zu erhalten

Abstract

Background Anticoagulation therapy with anti-vitamin K (AVK; vitamin K antagonist) for the prevention of thromboembolism in patients with atrial fibrillation (AF) is based on information derived from numerous well constructed, randomized controlled trials. Despite this conclusive evidence of efficacy, several studies have shown that ‘real world’ use of AVK in patients with AF is suboptimal. Our hypothesis was that geriatric characteristics (functional impairment, cognitive disorders, malnutrition, risk for falls, depression) could be an explanation for the underprescription of AVK in older patients with AF.
Objective To analyse the barriers to the prescription of AVK therapy, with special attention on geriatric characteristics.
Methods This was a retrospective study of 768 consecutive geriatric patients admitted to an acute geriatric unit of an academic hospital between April 2006 and November 2008. Data from comprehensive geriatric assessments were collected from computerized medical charts.
Results Analysis of data from the 768 medical charts showed that 111 patients (14%) presented with AF. Among the 111 patients (72% women), 45% were living in an institution before admission. These patients presented a high prevalence of geriatric syndromes: cognitive disorders 59%, malnutrition risk 59%, incontinence 35%, depression 37%, and falls 61%. Ninety percent of the patients had an Identification of Seniors At Risk (ISAR) questionnaire score ≥2, which indicates an increased risk of frailty and functional decline during hospitalization. The prevalence of conditions measured by the CHADS2 (congestive heart failure, hypertension, age >75 years, diabetes mellitus and previous stroke or transient ischaemic attack [TIA]) clinical prediction scale was as follows: heart failure 19%, hypertension 79%, age >75 years 95%, diabetes 15% and stroke 24%. The mean ± SD number of daily classes of drugs received at admission was 7.1±3.3 (median 7, range 0–20). Forty-nine percent of patients had not received any AVK treatment before admission. The level of functional dependence for basic and instrumental activities of daily living did not differ between patients receiving AVK before admission and those not receiving AVK. Similarly, the proportion of geriatric problems (cognitive, malnutrition, depression and falls) did not differ between these two groups. To determine whether the decision to administer AVK therapy before admission was influenced by the risk of an embolic stroke, determined by the presence of CHADS2 conditions, we compared the proportions of patients who fulfilled those conditions in each group: again, no difference was found.
Conclusions Almost half of the patients presenting with AF did not receive any AVK therapy before admission. In this population, in which most patients had multiple impairments, no single impairment or geriatric characteristic was identified as a barrier to AVK use. It is possible that combinations of impairments and geriatric characteristics were barriers to the prescription of AVK therapy across the whole of this population. More research is needed to identify and clarify the relative importance of patient-, physician- and healthcare system-related barriers to the prescription of AVK therapy in older patients with AF.
Literatur
1.
Zurück zum Zitat Gallagher AM, Rietbrock S, Plumb J, et al. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 2008 Sep; 6(9): 1500–6PubMedCrossRef Gallagher AM, Rietbrock S, Plumb J, et al. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 2008 Sep; 6(9): 1500–6PubMedCrossRef
2.
Zurück zum Zitat Morgan CL, McEwan P, Tukiendorf A, et al. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thrombosis Res 2009 May; 124(1): 37–41CrossRef Morgan CL, McEwan P, Tukiendorf A, et al. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thrombosis Res 2009 May; 124(1): 37–41CrossRef
3.
Zurück zum Zitat Thomson R, Eccles M, Wood R, et al. A cautionary note on data sources for evidence-based clinical decisions: warfarin and stroke prevention. Med Decis Making 2007 Jul–Aug; 27(4): 438–47PubMedCrossRef Thomson R, Eccles M, Wood R, et al. A cautionary note on data sources for evidence-based clinical decisions: warfarin and stroke prevention. Med Decis Making 2007 Jul–Aug; 27(4): 438–47PubMedCrossRef
4.
Zurück zum Zitat Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999 Oct 5; 131(7): 492–501PubMed Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999 Oct 5; 131(7): 492–501PubMed
5.
Zurück zum Zitat Albers GW, Bittar N, Young L, et al. Clinical characteristics and management of acute stroke in patients with atrial fibrillation admitted to US university hospitals. Neurology 1997 Jun; 48(6): 1598–604PubMedCrossRef Albers GW, Bittar N, Young L, et al. Clinical characteristics and management of acute stroke in patients with atrial fibrillation admitted to US university hospitals. Neurology 1997 Jun; 48(6): 1598–604PubMedCrossRef
6.
Zurück zum Zitat Antani MR, Beyth RJ, Covinsky KE, et al. Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation. J Gen Intern Med 1996 Dec; 11(12): 713–20PubMedCrossRef Antani MR, Beyth RJ, Covinsky KE, et al. Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation. J Gen Intern Med 1996 Dec; 11(12): 713–20PubMedCrossRef
7.
Zurück zum Zitat Beyth RJ, Antani MR, Covinsky KE, et al. Why isn’t warfarin prescribed to patients with nonrheumatic atrial fibrillation? J Gen Intern Med 1996 Dec; 11(12): 721–8PubMedCrossRef Beyth RJ, Antani MR, Covinsky KE, et al. Why isn’t warfarin prescribed to patients with nonrheumatic atrial fibrillation? J Gen Intern Med 1996 Dec; 11(12): 721–8PubMedCrossRef
8.
Zurück zum Zitat Bath PM, Prasad A, Brown MM, et al. Survey of use of anticoagulation in patients with atrial fibrillation. BMJ 1993 Oct 23; 307(6911): 1045PubMedCrossRef Bath PM, Prasad A, Brown MM, et al. Survey of use of anticoagulation in patients with atrial fibrillation. BMJ 1993 Oct 23; 307(6911): 1045PubMedCrossRef
9.
Zurück zum Zitat Brass LM, Krumholz HM, Scinto JM, et al. Warfarin use among patients with atrial fibrillation. Stroke 1997 Dec; 28(12): 2382–9PubMedCrossRef Brass LM, Krumholz HM, Scinto JM, et al. Warfarin use among patients with atrial fibrillation. Stroke 1997 Dec; 28(12): 2382–9PubMedCrossRef
10.
Zurück zum Zitat Gurwitz JH, Monette J, Rochon PA, et al. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med 1997 May 12; 157(9): 978–84PubMedCrossRef Gurwitz JH, Monette J, Rochon PA, et al. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med 1997 May 12; 157(9): 978–84PubMedCrossRef
11.
Zurück zum Zitat Monette J, Gurwitz JH, Rochon PA, et al. Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners. J Am Geriatr Soc 1997 Sep; 45(9): 1060–5PubMed Monette J, Gurwitz JH, Rochon PA, et al. Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners. J Am Geriatr Soc 1997 Sep; 45(9): 1060–5PubMed
12.
Zurück zum Zitat Munschauer FE, Priore RL, Hens M, et al. Thromboembolism prophylaxis in chronic atrial fibrillation: practice patterns in community and tertiary-care hospitals. Stroke 1997 Jan; 28(1): 72–6PubMedCrossRef Munschauer FE, Priore RL, Hens M, et al. Thromboembolism prophylaxis in chronic atrial fibrillation: practice patterns in community and tertiary-care hospitals. Stroke 1997 Jan; 28(1): 72–6PubMedCrossRef
13.
Zurück zum Zitat Fang MC, Stafford RS, Ruskin JN, et al. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med 2004 Jan 12; 164(1): 55–60PubMedCrossRef Fang MC, Stafford RS, Ruskin JN, et al. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med 2004 Jan 12; 164(1): 55–60PubMedCrossRef
14.
Zurück zum Zitat Cohen N, Almoznino-Sarafian D, Alon I, et al. Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. Stroke 2000 Jun; 31(6): 1217–22PubMedCrossRef Cohen N, Almoznino-Sarafian D, Alon I, et al. Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. Stroke 2000 Jun; 31(6): 1217–22PubMedCrossRef
15.
Zurück zum Zitat Majeed A, Moser K, Carroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994–1998: analysis of data from the general practice research database. Heart 2001 Sep; 86(3): 284–8PubMedCrossRef Majeed A, Moser K, Carroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994–1998: analysis of data from the general practice research database. Heart 2001 Sep; 86(3): 284–8PubMedCrossRef
16.
Zurück zum Zitat Stewart S, Murphy NF, Walker A, et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004 Mar; 90(3): 286–92PubMedCrossRef Stewart S, Murphy NF, Walker A, et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004 Mar; 90(3): 286–92PubMedCrossRef
17.
Zurück zum Zitat Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation: does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994 Sep 12; 154(17): 1945–53PubMedCrossRef Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation: does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994 Sep 12; 154(17): 1945–53PubMedCrossRef
18.
Zurück zum Zitat Brodsky MA, Chun JG, Podrid PJ, et al. Regional attitudes of generalists, specialists, and subspecialists about management of atrial fibrillation. Arch Intern Med 1996 Dec 9–23; 156(22): 2553–62PubMedCrossRef Brodsky MA, Chun JG, Podrid PJ, et al. Regional attitudes of generalists, specialists, and subspecialists about management of atrial fibrillation. Arch Intern Med 1996 Dec 9–23; 156(22): 2553–62PubMedCrossRef
19.
Zurück zum Zitat Brodsky MA, Podrid PJ, Chun JG. Should physicians participate in affirming the best approach to atrial fibrillation management? Am J Cardiol 1996 Nov 15; 78(10): 1152–3PubMedCrossRef Brodsky MA, Podrid PJ, Chun JG. Should physicians participate in affirming the best approach to atrial fibrillation management? Am J Cardiol 1996 Nov 15; 78(10): 1152–3PubMedCrossRef
20.
Zurück zum Zitat Chang HJ, Bell JR, Deroo DB, et al. Physician variation in anticoagulating patients with atrial fibrillation. Dartmouth Primary Care COOP Project. Arch Intern Med 1990 Jan; 150(1): 83–6PubMedCrossRef Chang HJ, Bell JR, Deroo DB, et al. Physician variation in anticoagulating patients with atrial fibrillation. Dartmouth Primary Care COOP Project. Arch Intern Med 1990 Jan; 150(1): 83–6PubMedCrossRef
21.
Zurück zum Zitat Kutner M, Nixon G, Silverstone F. Physicians’ attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med 1991 Oct; 151(10): 1950–3PubMedCrossRef Kutner M, Nixon G, Silverstone F. Physicians’ attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med 1991 Oct; 151(10): 1950–3PubMedCrossRef
22.
Zurück zum Zitat Lip GY, Zarifis J, Watson RD, et al. Physician variation in the management of patients with atrial fibrillation. Heart 1996 Feb; 75(2): 200–5PubMedCrossRef Lip GY, Zarifis J, Watson RD, et al. Physician variation in the management of patients with atrial fibrillation. Heart 1996 Feb; 75(2): 200–5PubMedCrossRef
23.
Zurück zum Zitat McCrory DC, Matchar DB, Samsa G, et al. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995 Feb 13; 155(3): 277–81PubMedCrossRef McCrory DC, Matchar DB, Samsa G, et al. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995 Feb 13; 155(3): 277–81PubMedCrossRef
24.
Zurück zum Zitat Buksinska-Lisik M. BAFTA Study. Comparison of aspirin and warfarin in preventive maintenance of stroke in the oldest persons with atrial fibrillation. Kardiol Pol 2007 Nov; 65(11): 1399–400PubMed Buksinska-Lisik M. BAFTA Study. Comparison of aspirin and warfarin in preventive maintenance of stroke in the oldest persons with atrial fibrillation. Kardiol Pol 2007 Nov; 65(11): 1399–400PubMed
25.
Zurück zum Zitat Di Pasquale G, Palareti G. The BAFTA study. G Ital Cardiol 2008 Nov; 9(11): 735–9 Di Pasquale G, Palareti G. The BAFTA study. G Ital Cardiol 2008 Nov; 9(11): 735–9
26.
Zurück zum Zitat Diug B, Lowthian J, Evans S. Warfarin versus aspirin for stroke prevention (BAFTA). Lancet 2007 Nov 10; 370(9599): 1606; author reply: 7PubMedCrossRef Diug B, Lowthian J, Evans S. Warfarin versus aspirin for stroke prevention (BAFTA). Lancet 2007 Nov 10; 370(9599): 1606; author reply: 7PubMedCrossRef
27.
Zurück zum Zitat Hart RG. Did we really need another comparison of warfarin with aspirin? An assessment of the BAFTA trial. Pol Arch Med Wewn 2007 Oct; 117(10): 443–5PubMed Hart RG. Did we really need another comparison of warfarin with aspirin? An assessment of the BAFTA trial. Pol Arch Med Wewn 2007 Oct; 117(10): 443–5PubMed
28.
Zurück zum Zitat Hurley V, Ireson R, Fletcher K, et al. A cross-sectional study of hypertension in an elderly population (75 years and over) with atrial fibrillation: secondary analysis of data from the Birmingham Atrial Fibrillation in the Aged (BAFTA) randomised controlled trial. Int J Cardiol 2007 Apr 25; 117(2): 152–6PubMedCrossRef Hurley V, Ireson R, Fletcher K, et al. A cross-sectional study of hypertension in an elderly population (75 years and over) with atrial fibrillation: secondary analysis of data from the Birmingham Atrial Fibrillation in the Aged (BAFTA) randomised controlled trial. Int J Cardiol 2007 Apr 25; 117(2): 152–6PubMedCrossRef
29.
Zurück zum Zitat Liakishev AA. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation. Results of the BAFTA trial. Kardiologia 2008; 48(2): 68 Liakishev AA. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation. Results of the BAFTA trial. Kardiologia 2008; 48(2): 68
30.
Zurück zum Zitat Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007 Aug 11; 370(9586): 493–503PubMedCrossRef Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007 Aug 11; 370(9586): 493–503PubMedCrossRef
31.
Zurück zum Zitat Mant JW, Richards SH, Hobbs FD, et al. Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN89345269]. BMC Cardiovasc Disord 2003 Aug 26; 3: 9–18PubMedCrossRef Mant JW, Richards SH, Hobbs FD, et al. Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN89345269]. BMC Cardiovasc Disord 2003 Aug 26; 3: 9–18PubMedCrossRef
32.
Zurück zum Zitat Mihas C, Alevizos A, Arapaki A, et al. Warfarin versus aspirin for stroke prevention (BAFTA). Lancet 2007 Nov 10; 370(9599): 1606; author reply: 7PubMedCrossRef Mihas C, Alevizos A, Arapaki A, et al. Warfarin versus aspirin for stroke prevention (BAFTA). Lancet 2007 Nov 10; 370(9599): 1606; author reply: 7PubMedCrossRef
33.
Zurück zum Zitat Sudlow C, Warlow C. First-ever stroke incidence [letter]. Lancet 1998 Jun 20; 351(9119): 1892PubMedCrossRef Sudlow C, Warlow C. First-ever stroke incidence [letter]. Lancet 1998 Jun 20; 351(9119): 1892PubMedCrossRef
34.
Zurück zum Zitat Sudlow M, Thomson R, Thwaites B, et al. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998 Oct 10; 352(9135): 1167–71PubMedCrossRef Sudlow M, Thomson R, Thwaites B, et al. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998 Oct 10; 352(9135): 1167–71PubMedCrossRef
35.
Zurück zum Zitat Kalra L, Perez I, Melbourn A. Risk assessment and anticoagulation for primary stroke prevention in atrial fibrillation. Stroke 1999 Jun; 30(6): 1218–22PubMedCrossRef Kalra L, Perez I, Melbourn A. Risk assessment and anticoagulation for primary stroke prevention in atrial fibrillation. Stroke 1999 Jun; 30(6): 1218–22PubMedCrossRef
36.
Zurück zum Zitat Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med 1999 Dec 21; 131(12): 927–34PubMed Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med 1999 Dec 21; 131(12): 927–34PubMed
37.
Zurück zum Zitat Bungard TJ, Ghali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000 Jan 10; 160(1): 41–6PubMedCrossRef Bungard TJ, Ghali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000 Jan 10; 160(1): 41–6PubMedCrossRef
38.
Zurück zum Zitat Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963 Sep 21; 185: 914–9PubMedCrossRef Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963 Sep 21; 185: 914–9PubMedCrossRef
39.
Zurück zum Zitat Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969 Autumn; 9(3): 179–86PubMedCrossRef Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969 Autumn; 9(3): 179–86PubMedCrossRef
40.
Zurück zum Zitat Yesavage JA. Geriatric depression scale. Psychopharmacol Bull 1988; 24(4): 709–11PubMed Yesavage JA. Geriatric depression scale. Psychopharmacol Bull 1988; 24(4): 709–11PubMed
41.
Zurück zum Zitat Stratton RJ, Hackston A, Longmore D, et al. Malnutrition in hospital outpatients and inpatients: prevalence, concurrent validity and ease of use of the ‘malnutrition universal screening tool’ (‘MUST’) for adults. Br J Nutr 2004 Nov; 92(5): 799–808PubMedCrossRef Stratton RJ, Hackston A, Longmore D, et al. Malnutrition in hospital outpatients and inpatients: prevalence, concurrent validity and ease of use of the ‘malnutrition universal screening tool’ (‘MUST’) for adults. Br J Nutr 2004 Nov; 92(5): 799–808PubMedCrossRef
42.
Zurück zum Zitat Pepersack T. Minimum geriatric screening tools to detect common geriatric problems. J Nutr Health Aging 2008 May; 12(5): 348–52PubMedCrossRef Pepersack T. Minimum geriatric screening tools to detect common geriatric problems. J Nutr Health Aging 2008 May; 12(5): 348–52PubMedCrossRef
43.
Zurück zum Zitat Gillespie LD, Gillespie WJ, Cumming R, et al. Interventions for preventing falls in the elderly. Cochrane Database Syst Rev 2000; 2: CD000340PubMed Gillespie LD, Gillespie WJ, Cumming R, et al. Interventions for preventing falls in the elderly. Cochrane Database Syst Rev 2000; 2: CD000340PubMed
44.
Zurück zum Zitat Bond AJ, Molnar FJ, Li M, et al. The risk of hemorrhagic complications in hospital in-patients who fall while receiving antithrombotic therapy. Thromb J 2005 Jan 7; 3(1): 1PubMedCrossRef Bond AJ, Molnar FJ, Li M, et al. The risk of hemorrhagic complications in hospital in-patients who fall while receiving antithrombotic therapy. Thromb J 2005 Jan 7; 3(1): 1PubMedCrossRef
45.
Zurück zum Zitat Choudhry NK, Soumerai SB, Normand SL, et al. Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics. Am J Med 2006 Jul; 119(7): 607–15PubMedCrossRef Choudhry NK, Soumerai SB, Normand SL, et al. Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics. Am J Med 2006 Jul; 119(7): 607–15PubMedCrossRef
46.
Zurück zum Zitat Connolly SJ. Preventing stroke in atrial fibrillation: why are so many eligible patients not receiving anticoagulant therapy? CMAJ 1999 Sep 7; 161(5): 533–4PubMed Connolly SJ. Preventing stroke in atrial fibrillation: why are so many eligible patients not receiving anticoagulant therapy? CMAJ 1999 Sep 7; 161(5): 533–4PubMed
47.
Zurück zum Zitat Man-Son-Hing M, Nichol G, Lau A, et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999 Apr 12; 159(7): 677–85PubMedCrossRef Man-Son-Hing M, Nichol G, Lau A, et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999 Apr 12; 159(7): 677–85PubMedCrossRef
48.
Zurück zum Zitat Howitt A, Armstrong D. Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation. BMJ 1999 May 15; 318(7194): 1324–7PubMedCrossRef Howitt A, Armstrong D. Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation. BMJ 1999 May 15; 318(7194): 1324–7PubMedCrossRef
49.
Zurück zum Zitat Protheroe J, Fahey T, Montgomery AA, et al. The impact of patients’ preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ 2000 May 20; 320(7246): 1380–4PubMedCrossRef Protheroe J, Fahey T, Montgomery AA, et al. The impact of patients’ preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ 2000 May 20; 320(7246): 1380–4PubMedCrossRef
50.
Zurück zum Zitat Pepersack T, Corretge M, Beyer I, et al. Examining the effect of intervention to nutritional problems of hospitalised elderly: a pilot project. J Nutr Health Aging 2002; 6(5): 306–10PubMed Pepersack T, Corretge M, Beyer I, et al. Examining the effect of intervention to nutritional problems of hospitalised elderly: a pilot project. J Nutr Health Aging 2002; 6(5): 306–10PubMed
51.
Zurück zum Zitat O’Reilly RA. Interaction of the anticoagulant drug warfarin and its metabolites with human plasma albumin. J Clin Investig 1969 Jan; 48(1): 193–202PubMedCrossRef O’Reilly RA. Interaction of the anticoagulant drug warfarin and its metabolites with human plasma albumin. J Clin Investig 1969 Jan; 48(1): 193–202PubMedCrossRef
52.
Zurück zum Zitat Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998 Aug; 105(2): 91–9PubMedCrossRef Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998 Aug; 105(2): 91–9PubMedCrossRef
53.
Zurück zum Zitat Aspinall SL, DeSanzo BE, Trilli LE, et al. Bleeding risk index in an anticoagulation clinic: assessment by indication and implications for care. J Gen Intern Med 2005 Nov; 20(11): 1008–13PubMedCrossRef Aspinall SL, DeSanzo BE, Trilli LE, et al. Bleeding risk index in an anticoagulation clinic: assessment by indication and implications for care. J Gen Intern Med 2005 Nov; 20(11): 1008–13PubMedCrossRef
54.
Zurück zum Zitat Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989 Aug; 87(2): 144–52PubMedCrossRef Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989 Aug; 87(2): 144–52PubMedCrossRef
55.
Zurück zum Zitat Davis DA, Thomson MA, Oxman AD, et al. Changing physician performance: a systematic review of the effect of continuing medical education strategies. JAMA 1995 Sep 6; 274(9): 700–5PubMedCrossRef Davis DA, Thomson MA, Oxman AD, et al. Changing physician performance: a systematic review of the effect of continuing medical education strategies. JAMA 1995 Sep 6; 274(9): 700–5PubMedCrossRef
Metadaten
Titel
Could Geriatric Characteristics Explain the Under-Prescription of Anticoagulation Therapy for Older Patients Admitted with Atrial Fibrillation?
A Retrospective Observational Study
verfasst von
Sandra De Breucker
Gertraud Herzog
Dr Thierry Pepersack
Publikationsdatum
01.10.2010
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 10/2010
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.2165/11537900-000000000-00000

Weitere Artikel der Ausgabe 10/2010

Drugs & Aging 10/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.